Targeting NK cells to enhance melanoma response to immunotherapies
April 5, 2021
Abstract
NK cells are innate immune cells that form one of the initial responses to infections and cancers. There have been increasing number of studies investigating the anti-tumor effects of NK cells. Immunotherapy targeting NK cell may enhance the therapeutic efficacy of current immunotherapy regimes. Through pro-inflammatory cytokine production, enhancing B cell production of antibodies, facilitate and activate dendritic cells, activate T cells and participating in anti-tumor immunity through the granzyme B pathway and antibody-dependent cellular cytotoxicity, the versatility of NK cells provides an attractive immunotherapy option. This review highlights NK cell biology, NK cell antitumor immunity, NK cell immune evasive mechanisms and novel immunotherapies that aim to target NK cells.
Source:
Lee, H., Da Silva, I. P., Palendira, U., Scolyer, R. A., Long, G. V., & Wilmott, J. S. (2021). Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. Cancers, 13(6), 1363. https://doi.org/10.3390/cancer...